Employing novel indirect treatment comparison methodologies to differentiate the efficacy of ofatumumab versus orally administered therapies for relapsing multiple sclerosis

被引：0

作者：

Butzkueven, Helmut ^{[1
]}

Haltner, Anja ^{[2
]}

Drudge, Chris ^{[3
]}

Samjoo, Imtiaz ^{[3
]}

Barnett, Michael ^{[4
,5
]}

Broadley, Simon ^{[6
]}

Mccombe, Pamela ^{[7
]}

Van der Walt, Anneke ^{[1
]}

Stoneman, Dee ^{[8
]}

Merschhemke, Martin ^{[8
]}

Adlard, Nicholas ^{[8
]}

Nelson, Morag ^{[9
]}

Riley, Nicholas ^{[9
]}

Walker, Rob ^{[9
]}

机构：

[1] Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Vic, Australia

[2] Eversana, Chicago, IL USA

[3] Eversana, Burlington, ON, Canada

[4] Univ Sydney, Brain & Mind Ctr, Camperdown, NSW, Australia

[5] Royal Prince Alfred Hosp, Camperdown, NSW, Australia

[6] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld, Australia

[7] Univ Queensland, St Lucia, Qld, Australia

[8] Novartis Pharma AG, Basel, Switzerland

[9] Novartis Pharmaceut Australia, Sydney, NSW, Australia

来源：

关键词：

ofatumumab; indirect treatment comparison; health economics; disease modifying therapy; relapsing MS;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：50 / 51

页数：2